In its latest bid to address health care costs, the Food and Drug Administration issued a new guidance that offers suggestions for drug makers seeking to switch their prescription medicines to a so-called non-prescription status.

The guidance, which the agency called a “first step,” is designed to encourage drug makers to think about ways to seek approval for over-the-counter approvals. A new FDA regulation that would formalize such an approach is expected next year, but the agency emphasized that approval standards for over-the-counter medicines are not being lowered.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Greetings,

    I already entered all of my payment method information. I need someone to call me to undestand why is asking me to complete the subscription when I already did and does not let me access the articles I would like to read?


    David Lugo

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy